Role of biomarkers in studies of presymptomatic Alzheimer's disease

John C. Morris, Kimberly A. Quaid K, David M. Holtzman, Kejal Kantarci, Jeffrey Kaye, Eric M. Reiman, William E. Klunk, Eric R. Siemers

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Biomarkers that have been developed largely for the study of patients with clinically diagnosed Alzheimer's disease (AD) can also be used in the study of cognitively normal individuals who may harbor underlying AD pathology. Methods: A meeting of invited experts on AD biomarkers was held on November 11 and 12, 2004 to review currently available data and to discuss unmet needs for biomarker research in presymptomatic AD. Results: Neuroimaging biomarkers have been studied to some extent in subjects at risk for AD. These imaging techniques include volumetric magnetic resonance imaging and positron emission tomography using either fluorodeoxyglucose or newer ligands that bind directly to amyloid plaque. Similarly, biochemical measures from cerebrospinal fluid or other physiologic fluids are emerging as potentially useful tools. Such biomarkers may be used either as diagnostic tools or as indicators of disease severity when followed longitudinally. A clinical diagnosis of asymptomatic individuals using biomarkers and studies involving asymptomatic subjects may raise logistical and ethical concerns. Conclusions: The technical development of biomarkers that are used for presymptomatic AD diagnosis and for longitudinally measuring disease severity is evolving rapidly. Ethical and privacy considerations must be made before such biomarkers can be applied routinely to asymptomatic populations.

Original languageEnglish
Pages (from-to)145-151
Number of pages7
JournalAlzheimer's and Dementia
Volume1
Issue number2
DOIs
StatePublished - Oct 2005

Fingerprint

Asymptomatic Diseases
Alzheimer Disease
Biomarkers
Privacy
Amyloid Plaques
Neuroimaging
Positron-Emission Tomography
Cerebrospinal Fluid
Magnetic Resonance Imaging
Pathology
Ligands

Keywords

  • Alzheimer's disease
  • Amyloid beta
  • Biomarkers
  • Cerebrospinal fluid
  • Positron emission tomography
  • Tau
  • Volumetric magnetic resonance imaging

ASJC Scopus subject areas

  • Health Policy
  • Epidemiology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

Morris, J. C., Quaid K, K. A., Holtzman, D. M., Kantarci, K., Kaye, J., Reiman, E. M., ... Siemers, E. R. (2005). Role of biomarkers in studies of presymptomatic Alzheimer's disease. Alzheimer's and Dementia, 1(2), 145-151. https://doi.org/10.1016/j.jalz.2005.09.013

Role of biomarkers in studies of presymptomatic Alzheimer's disease. / Morris, John C.; Quaid K, Kimberly A.; Holtzman, David M.; Kantarci, Kejal; Kaye, Jeffrey; Reiman, Eric M.; Klunk, William E.; Siemers, Eric R.

In: Alzheimer's and Dementia, Vol. 1, No. 2, 10.2005, p. 145-151.

Research output: Contribution to journalArticle

Morris, JC, Quaid K, KA, Holtzman, DM, Kantarci, K, Kaye, J, Reiman, EM, Klunk, WE & Siemers, ER 2005, 'Role of biomarkers in studies of presymptomatic Alzheimer's disease', Alzheimer's and Dementia, vol. 1, no. 2, pp. 145-151. https://doi.org/10.1016/j.jalz.2005.09.013
Morris JC, Quaid K KA, Holtzman DM, Kantarci K, Kaye J, Reiman EM et al. Role of biomarkers in studies of presymptomatic Alzheimer's disease. Alzheimer's and Dementia. 2005 Oct;1(2):145-151. https://doi.org/10.1016/j.jalz.2005.09.013
Morris, John C. ; Quaid K, Kimberly A. ; Holtzman, David M. ; Kantarci, Kejal ; Kaye, Jeffrey ; Reiman, Eric M. ; Klunk, William E. ; Siemers, Eric R. / Role of biomarkers in studies of presymptomatic Alzheimer's disease. In: Alzheimer's and Dementia. 2005 ; Vol. 1, No. 2. pp. 145-151.
@article{b93cea40efed4b98893fcbd8d49a2675,
title = "Role of biomarkers in studies of presymptomatic Alzheimer's disease",
abstract = "Background: Biomarkers that have been developed largely for the study of patients with clinically diagnosed Alzheimer's disease (AD) can also be used in the study of cognitively normal individuals who may harbor underlying AD pathology. Methods: A meeting of invited experts on AD biomarkers was held on November 11 and 12, 2004 to review currently available data and to discuss unmet needs for biomarker research in presymptomatic AD. Results: Neuroimaging biomarkers have been studied to some extent in subjects at risk for AD. These imaging techniques include volumetric magnetic resonance imaging and positron emission tomography using either fluorodeoxyglucose or newer ligands that bind directly to amyloid plaque. Similarly, biochemical measures from cerebrospinal fluid or other physiologic fluids are emerging as potentially useful tools. Such biomarkers may be used either as diagnostic tools or as indicators of disease severity when followed longitudinally. A clinical diagnosis of asymptomatic individuals using biomarkers and studies involving asymptomatic subjects may raise logistical and ethical concerns. Conclusions: The technical development of biomarkers that are used for presymptomatic AD diagnosis and for longitudinally measuring disease severity is evolving rapidly. Ethical and privacy considerations must be made before such biomarkers can be applied routinely to asymptomatic populations.",
keywords = "Alzheimer's disease, Amyloid beta, Biomarkers, Cerebrospinal fluid, Positron emission tomography, Tau, Volumetric magnetic resonance imaging",
author = "Morris, {John C.} and {Quaid K}, {Kimberly A.} and Holtzman, {David M.} and Kejal Kantarci and Jeffrey Kaye and Reiman, {Eric M.} and Klunk, {William E.} and Siemers, {Eric R.}",
year = "2005",
month = "10",
doi = "10.1016/j.jalz.2005.09.013",
language = "English",
volume = "1",
pages = "145--151",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Role of biomarkers in studies of presymptomatic Alzheimer's disease

AU - Morris, John C.

AU - Quaid K, Kimberly A.

AU - Holtzman, David M.

AU - Kantarci, Kejal

AU - Kaye, Jeffrey

AU - Reiman, Eric M.

AU - Klunk, William E.

AU - Siemers, Eric R.

PY - 2005/10

Y1 - 2005/10

N2 - Background: Biomarkers that have been developed largely for the study of patients with clinically diagnosed Alzheimer's disease (AD) can also be used in the study of cognitively normal individuals who may harbor underlying AD pathology. Methods: A meeting of invited experts on AD biomarkers was held on November 11 and 12, 2004 to review currently available data and to discuss unmet needs for biomarker research in presymptomatic AD. Results: Neuroimaging biomarkers have been studied to some extent in subjects at risk for AD. These imaging techniques include volumetric magnetic resonance imaging and positron emission tomography using either fluorodeoxyglucose or newer ligands that bind directly to amyloid plaque. Similarly, biochemical measures from cerebrospinal fluid or other physiologic fluids are emerging as potentially useful tools. Such biomarkers may be used either as diagnostic tools or as indicators of disease severity when followed longitudinally. A clinical diagnosis of asymptomatic individuals using biomarkers and studies involving asymptomatic subjects may raise logistical and ethical concerns. Conclusions: The technical development of biomarkers that are used for presymptomatic AD diagnosis and for longitudinally measuring disease severity is evolving rapidly. Ethical and privacy considerations must be made before such biomarkers can be applied routinely to asymptomatic populations.

AB - Background: Biomarkers that have been developed largely for the study of patients with clinically diagnosed Alzheimer's disease (AD) can also be used in the study of cognitively normal individuals who may harbor underlying AD pathology. Methods: A meeting of invited experts on AD biomarkers was held on November 11 and 12, 2004 to review currently available data and to discuss unmet needs for biomarker research in presymptomatic AD. Results: Neuroimaging biomarkers have been studied to some extent in subjects at risk for AD. These imaging techniques include volumetric magnetic resonance imaging and positron emission tomography using either fluorodeoxyglucose or newer ligands that bind directly to amyloid plaque. Similarly, biochemical measures from cerebrospinal fluid or other physiologic fluids are emerging as potentially useful tools. Such biomarkers may be used either as diagnostic tools or as indicators of disease severity when followed longitudinally. A clinical diagnosis of asymptomatic individuals using biomarkers and studies involving asymptomatic subjects may raise logistical and ethical concerns. Conclusions: The technical development of biomarkers that are used for presymptomatic AD diagnosis and for longitudinally measuring disease severity is evolving rapidly. Ethical and privacy considerations must be made before such biomarkers can be applied routinely to asymptomatic populations.

KW - Alzheimer's disease

KW - Amyloid beta

KW - Biomarkers

KW - Cerebrospinal fluid

KW - Positron emission tomography

KW - Tau

KW - Volumetric magnetic resonance imaging

UR - http://www.scopus.com/inward/record.url?scp=33644806001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644806001&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2005.09.013

DO - 10.1016/j.jalz.2005.09.013

M3 - Article

VL - 1

SP - 145

EP - 151

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 2

ER -